This is just a tiny glimpse of the data available to CivicScience clients. Discover more data. CivicScience has data on over ...

Approximately 15.5 million Americans have been or currently are on injectable diabetes or weight-loss medications known as ...

Food companies are capitalizing on the GLP-1 trend, offering high-protein, portion-controlled meals. But are they meeting ...

The GLP-1 drug, exenatide, has no positive impact on the movement, symptoms or brain imaging of people with Parkinson's, ...

Scouted selects products independently. If you purchase something from our posts, we may earn a small commission. Unless you ...

A small percentage of patients taking GLP-1 medications have experienced vision problems, but a direct causal link with the ...

A study on GLP1RA medications found that behavioral side effects likely do not result from direct action on GLP1R.

The GLP-1 drug, exenatide, has no positive impact on the movement, symptoms or brain imaging of people with Parkinson's, finds a new study led by UCL researchers.

Roche Holding AG delivered a strong set of 2024 earnings. Guidance for 2025 suggests this will be a transitional year ahead, ...

Wegovy is a GLP-1 agonist containing semaglutide, the same active ingredient as Ozempic. While both medications share this ...